Published in BMJ on March 28, 2014
Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study. Eur Urol (2015) 2.41
The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening. Urology (2016) 2.05
Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer. J Clin Oncol (2016) 1.48
Prostate cancer: Personalized risk - stratified screening or abandoning it altogether? Nat Rev Clin Oncol (2016) 1.00
Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study. Eur Urol (2016) 0.93
Gleason 6 Prostate Cancer: Translating Biology into Population Health. J Urol (2015) 0.91
An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care. Urology (2016) 0.86
PSA screening for prostate cancer. BMJ (2014) 0.78
The Effect of Start and Stop Age at Screening on the Risk of Being Diagnosed with Prostate Cancer. J Urol (2015) 0.78
The Lake Wobegon Effect: Why Most Patients Are at Below-Average Risk. Ann Intern Med (2015) 0.78
What's new in screening in 2015? Curr Opin Urol (2016) 0.77
Serial Percent Free Prostate Specific Antigen in Combination with Prostate Specific Antigen for Population Based Early Detection of Prostate Cancer. J Urol (2016) 0.76
Who and when should we screen for prostate cancer? Interviews with key opinion leaders. BMC Med (2015) 0.76
Prostate cancer screening in Brazil: should it be done or not? Int Braz J Urol (2016) 0.75
A targeted approach reduces prostate cancer-specific (PSA) screening harms while preserving benefits. Evid Based Med (2014) 0.75
Involving a Citizens' Jury in Decisions on Individual Screening for Prostate Cancer. PLoS One (2016) 0.75
Evidence-Based Versus Personalized Prostate Cancer Screening: Using Baseline Prostate-Specific Antigen Measurements to Individualize Screening. J Clin Oncol (2016) 0.75
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Prostate-cancer mortality at 11 years of follow-up. N Engl J Med (2012) 16.91
Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol (2010) 12.64
Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ (2010) 4.42
Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol (2007) 3.72
Baseline prostate-specific antigen testing at a young age. Eur Urol (2011) 2.95
Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer (2010) 2.90
Race, socioeconomic status and stage at diagnosis for five common malignancies. Cancer Causes Control (2003) 2.88
Balancing the harms and benefits of early detection of prostate cancer. Cancer (2010) 2.71
Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C. Clin Chem (2005) 2.05
Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin Chem (1995) 1.98
Prostate-specific antigen as predictor of prostate cancer in black men and white men. J Natl Cancer Inst (1995) 1.96
Prostate cancer incidence and disease-specific survival of men with initial prostate-specific antigen less than 3.0 ng/ml who are participating in ERSPC Rotterdam. Eur Urol (2011) 1.83
Risk-based prostate cancer screening. Eur Urol (2011) 1.64
Uptake of prostate-specific antigen testing for early prostate cancer detection in Sweden. Int J Cancer (2011) 1.47
Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of Black and White Americans. J Urol (2005) 1.42
Prostate cancer diagnosed after prostate-specific antigen testing of men without clinical signs of the disease: a population-based study from the National Prostate Cancer Register of Sweden. Scand J Urol Nephrol (2010) 0.98
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Prostate-cancer mortality at 11 years of follow-up. N Engl J Med (2012) 16.91
Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol (2010) 12.64
Quality-of-life effects of prostate-specific antigen screening. N Engl J Med (2012) 7.21
An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst (2011) 5.73
Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 5.36
Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? J Natl Cancer Inst (2008) 5.09
Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ (2010) 4.42
Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest (2006) 4.37
Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol (2010) 4.15
Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer (2008) 4.15
Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol (2012) 4.07
Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol (2006) 4.05
Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol (2008) 4.02
Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol (2010) 3.76
Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol (2007) 3.72
Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst (2007) 3.70
Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 3.53
Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam. J Natl Cancer Inst (2007) 3.26
Using relative utility curves to evaluate risk prediction. J R Stat Soc Ser A Stat Soc (2009) 3.04
Acupuncture for migraine prophylaxis. Cochrane Database Syst Rev (2009) 3.00
Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol (2008) 2.92
Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer (2010) 2.90
The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clin Cancer Res (2010) 2.87
The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell (2008) 2.87
Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial. Eur Urol (2012) 2.79
A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden. BMC Med (2008) 2.47
Acupuncture for tension-type headache. Cochrane Database Syst Rev (2009) 2.47
Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst (2010) 2.45
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med (2008) 2.39
Complications after radical and partial nephrectomy as a function of age. J Urol (2010) 2.36
Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. Eur Urol (2009) 2.31
NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw (2010) 2.31
Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol (2012) 2.28
A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol (2012) 2.27
PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer (2007) 2.27
Finasteride to prevent prostate cancer: should all men or only a high-risk subgroup be treated? J Clin Oncol (2010) 2.26
Extent of pelvic lymph node dissection and the impact of standard template dissection on nomogram prediction of lymph node involvement. Eur Urol (2011) 2.22
Prostate cancer imaging trends after a nationwide effort to discourage inappropriate prostate cancer imaging. J Natl Cancer Inst (2013) 2.20
Surveillance and deferred treatment for localized prostate cancer. Population based study in the National Prostate Cancer Register of Sweden. J Urol (2008) 2.17
Prostate cancer mortality in areas with high and low prostate cancer incidence. J Natl Cancer Inst (2014) 2.16
The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. Int J Cancer (2010) 2.15
TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol (2011) 2.14
Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 2.06
Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C. Clin Chem (2005) 2.05
Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol (2009) 2.05
N-acetyltransferase 2 phenotype, occupation, and bladder cancer risk: results from the EPIC cohort. Cancer Epidemiol Biomarkers Prev (2013) 2.01
Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study. Eur Urol (2012) 1.96
Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective, population-based randomized controlled trial. Eur Urol (2006) 1.94
No excess mortality after prostate biopsy: results from the European Randomized Study of Screening for Prostate Cancer. BJU Int (2010) 1.94
Lead time associated with screening for prostate cancer. Int J Cancer (2004) 1.93
Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol (2007) 1.93
Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer. J Urol (2010) 1.91
Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial. Int J Cancer (2002) 1.89
Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients. J Clin Oncol (2007) 1.88
Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen. Cancer Discov (2012) 1.87
Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men. Eur Urol (2011) 1.85
Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments. Anal Chem (2006) 1.84
Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review. J Clin Oncol (2012) 1.82
Contemporary use of partial nephrectomy at a tertiary care center in the United States. J Urol (2009) 1.78
Prostate cancer: estimating the benefits of PSA screening. Nat Rev Urol (2009) 1.76
Outcome of primary versus deferred radical prostatectomy in the National Prostate Cancer Register of Sweden Follow-Up Study. J Urol (2010) 1.75
Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst (2003) 1.73
Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res (2009) 1.68
Preoperative and intraoperative risk factors for side-specific positive surgical margins in laparoscopic radical prostatectomy for prostate cancer. Eur Urol (2006) 1.67
Incidence of prostate cancer after termination of screening in a population-based randomised screening trial. Eur Urol (2013) 1.64
Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer (2004) 1.63
Timing of curative treatment for prostate cancer: a systematic review. Eur Urol (2013) 1.63
Inherited genetic variant predisposes to aggressive but not indolent prostate cancer. Proc Natl Acad Sci U S A (2010) 1.59
Rituximab therapy of lymphoma is enhanced by orally administered (1-->3),(1-->4)-D-beta-glucan. Leuk Res (2005) 1.59
Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. Arch Intern Med (2005) 1.57
Systematic review of statistical methods used in molecular marker studies in cancer. Cancer (2008) 1.53
How do you know if you are any good? A surgeon performance feedback system for the outcomes of radical prostatectomy. Eur Urol (2011) 1.50
Impact of a multidisciplinary continuous quality improvement program on the positive surgical margin rate after laparoscopic radical prostatectomy. Eur Urol (2006) 1.50
Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable. J Urol (2003) 1.49
Randomized controlled trial of a special acupuncture technique for pain after thoracotomy. J Thorac Cardiovasc Surg (2008) 1.49
Against quantiles: categorization of continuous variables in epidemiologic research, and its discontents. BMC Med Res Methodol (2012) 1.47